Evan is the Managing Partner for SPRIG Equity. Evan serves on a number of healthcare boards. Previously, he was a General Partner at Accelmed Partners. Evan has led over 30 financings and has had 17 of his prior investments either be acquired or become public companies. He previously spent a decade with Abbott Labs leading the corporate venture arm, Abbott Ventures. Prior to Abbott, he was a Principal with ONSET Ventures focused on health tech investing. He has a diverse background of operating experience in the health tech space including the endoscopy, diabetes and ear, nose and throat markets having worked for Stryker Endoscopy, J&J LifeScan and Acclarent.

In addition to his medical device experience, Evan worked for the Investment Banking Group at J.P. Morgan Chase & Co and in the consulting practice at PriceWaterhouseCoopers.

Evan holds an MBA from the J.L. Kellogg Graduate School of Management and a BBA cum laude in Finance from Texas A&M University. For over a decade, he has been an adjunct professor at Kellogg teaching MedTech Entrepreneurship and serves on the Innovation and New Ventures (INVO) Advisory Board and N.XT Fund investment committee at Northwestern University.

Evan has lectured at numerous universities including Duke University, Tel Aviv University, Tulane University, and University of Tennessee Knoxville.

Rebecca Raabe brings two decades of operating, consulting, and investing experience in the medical technology sector to SPRIG Equity.

Rebecca began her career as an operator, working in both public companies (Abbott) and private medical device companies, including Ulthera (acquired by Merz) and Cayenne Medical (acquired by Zimmer). She held leadership roles across strategy and commercialization.

As an investor, Rebecca worked on Abbott’s corporate venture team, managing equity investments and helping develop new franchise strategies. She later joined Ballast Capital, evaluating transactions across the medtech landscape, and has also served as an advisor to Rx3 Growth Partners, an investment firm focused on growth-stage health and wellness consumer brands.

Before co-founding SPRIG Equity, Rebecca was a consultant with SPRIG Consulting, a leading strategy and commercialization firm that specializes in partnering with private medical technology companies.

She holds an MBA from Northwestern University’s Kellogg School of Management and a BA in Biochemical Sciences from Harvard University.

Katie founded and leads SPRIG Consulting, LLC. She is a strategic marketing professional with over 25 years of healthcare experience. Katie has worked with over 250 medical technology companies ranging from venture-backed start-ups to Fortune 500 companies. Throughout her career, Katie has focused on the entire spectrum of marketing needs: from early stage market development strategies to downstream launch execution and commercialization efforts. Projects led by Katie range from business plan refinement and market opportunity assessments to development of marketing strategies that include corporate/product positioning and brand development. Katie has demonstrated an aptitude for delivering flawless launch execution and commercialization strategy implementation in the US, EU and AP geographies. During her consulting tenure, Katie is proud to have named numerous medical companies, products, and technologies.

Prior to consulting, Katie had a successful career with Guidant Corporation (acquired) and Kensey Nash Corporation (acquired) launching new, novel technologies, such as thrombus management catheters, embolic protection devices, and coronary stents. Prior to working in medical technology, Katie spent six years in health care risk management for two major medical malpractice companies: CNA Insurance Companies and MMI Insurance Company. In her role, Katie worked directly with physicians, hospital administrators, health care systems, and managed care organizations.

Katie holds an MBA from Northwestern University’s Kellogg Graduate School of Management where she was awarded the Health Industry Management Scholarship for recognition of her leadership in the health industry. Katie is currently an adjunct Faculty member at the Kellogg School of Business, where for nearly a decade she has been a highly rated faculty member teaching medical product commercialization and financing. In addition to her MBA, Katie holds a BA in Environmental Sciences from the University of Vermont.

Katie is an independent board member on a public company board. She is an organizing member of the Medtech Women non-profit organization that produces the annual, sold-out conference, Medtech Vision.

Olivier Delporte is an international executive with over 20 years of sales, marketing and general management experience, mostly in the medical device industry. Prior to joining Miracor, he was Senior Vice President, Sales & Marketing, U.S. at PneumRx (acquired by BTG in 2015) and Vice President Commercial Operations, Sales and Marketing of Tryton Medical in Europe, Middle East and Africa. Previously, Olivier held leadership positions at Guidant Corporation and Abbott Vascular. Olivier has studied and worked in the U.S., France, Spain, and Belgium. He is currently a Director of Endotoxins Therapeutics. Olivier earned a Master’s Degree in Business from the Université Catholique de Louvain, Belgium, and a Master’s in Business Administration from The University of Chicago Booth School of Business.

Alexei is a surgeon and serial entrepreneur with two successful exits thus far. In his most notable role as founding CEO of SIA, he led the company through FDA-clearance, commercialization, NIH grant funding for a “first-and-only” indication in a new market, and pivotal trial initiation to achieve that indication. SIA achieved all this in less than four years and with only $6.3M in equity capital, while maintaining a developmental pipeline. After kicking off a $15M Series B fundraise that would later be oversubscribed and expanded, Alexei began his training in plastic surgery at Northwestern McGaw Medical Center. He remained active as an executive board member during his first 18 months of surgical residency, leading the process that culminated in SIA being acquired by Integra LifeSciences (Nasdaq: IART) in December of 2022. Following the completion of three years of surgical residency, he is now taking a sabbatical as he considers his next step.

In addition to his work at SIA, in 2020, Alexei simultaneously co-founded RapidRona, a shared-economy platform that connects clinical laboratories directly to consumers, and one of the first companies to bring a home PCR test to market. They were acquired by DMH in 2021. He has authored over 20 peer-reviewed publications and book chapters, and lectures on science and entrepreneurship at national and international meetings. He is listed as inventor on multiple patents and serves as an investor and board advisor to early-stage companies focused on nanotechnology, tissue engineering, radiofrequency ablation, and transseptal puncture. Alexei was also named one of Forbes’ “30 under 30” in 2018 and Crain’s “20 in their 20s” in 2019.

Chase brings his clinical, research, and entrepreneurial experience to Sprig Equity to identify, support, and finance opportunities in medical technologies.
As an assistant professor at the University of California, Los Angeles, and a practicing, board-certified emergency physician, Chase delivers unique clinical insights on market opportunities, adoption limitations, and access to key decision-makers across the Medtech landscape. His background in leading medical device implementation projects, publishing high-impact research on AI and clinical workflow tools, and advising early- to late-stage health tech ventures helps derisk emerging technologies and accelerate clinical integration.

Prior to his current role, Chase worked for Bank of America’s Healthcare Investment Banking group and Abbott Labs corporate venture arm (Abbott Ventures) where he helped structure financings and evaluate investment opportunities.

Chase holds a BA in Human Biology from Stanford University, an MBA from the Stanford Graduate School of Business, and an MD from the Perelman School of Medicine at the University of Pennsylvania. He completed his Emergency Medicine residency training at the University of California, Los Angeles. Chase also lectures graduate students, engineers, and physicians through the Biodesign program.

BACKGROUND:

• Serial HealthTech Founder/CEO of Shockwave (SWAV) which pioneered intravascular lithotripsy
• Founder/CEO of Avail Medsystems which removes barriers of in-person medical procedure collaboration

AREAS OF EXPERTISE:

• Market disruptor/innovator
• Operational excellence and private company leadership
• Strategic deal-making savvy

BACKGROUND:

• C-Suite Executive with leading tech companies – former Groupon interim CEO
• Direct-to-consumer technology stewardship
• Current CEO of Apax Partners portfolio company

AREAS OF EXPERTISE:

• Exceptional understanding of consumer behavior across numerous industries including healthcare (via Groupon)
• Business model innovation experience from other industries as healthcare products and services begin to evolve

BACKGROUND:

• Serial entrepreneur/ interventional cardiologist
• Runs most influential interventional cardiology conference in industry – 3D at Dartmouth University
• Founder of most promising next gen left atrial appendage device – Conformal Medical
• Professor of Medicine at Dartmouth Medical School
• SPRIG Equity team has over decade long relationship

AREAS OF EXPERTISE:

• Structural Heart / Interventional Cardiology
• Unparalleled FDA/CMS/KOL/industry relationships

BACKGROUND:

• Healthcare operator and investor
• Worked closely with SPRIG Equity team as technology scout in Israel
• Worked for largest healthcare VC firm in Israel
• CEO and Managing Partner of Shoni Health Ventures, an early stage HealthTech fund that is strategically affiliated with Sheba Medical Center

AREAS OF EXPERTISE:

• Early-stage and commercial technology / business model assessment
• Strong digital health and medical device experience
• Israeli innovation

BACKGROUND:

• Founder of BioQuest, one of the leading healthcare executive search firms in the US, that focuses exclusively on CEO, board, and VP level positions
• He has successfully completed 100+ CEO searches over the past 20 years
• Current board member of Absolutions Med

AREAS OF EXPERTISE:

• Unparalleled network in the medical device, diagnostic, and digital health space
• Can access and assess the best talent for accelerating companies